Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.
作者信息
DiNicolantonio James J, Barroso-Aranda Jorge, McCarty Mark F
机构信息
Department of Preventive Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
Clinica Libre de Adicciones, Tijuana, Mexico.
出版信息
Open Heart. 2021 Apr;8(1). doi: 10.1136/openhrt-2021-001655.
Abstract
摘要
相似文献
1
Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.伊维菌素在新冠肺炎晚期的抗炎活性可能反映了全身甘氨酸受体的激活。
Open Heart. 2021 Apr;8(1). doi: 10.1136/openhrt-2021-001655.
2
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
3
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?伊维菌素作为一种广谱宿主导向抗病毒药物：真有那么神？
Cells. 2020 Sep 15;9(9):2100. doi: 10.3390/cells9092100.
4
Standard Dose Ivermectin for COVID-19.用于治疗新冠肺炎的标准剂量伊维菌素
Chest. 2021 May;159(5):2111-2112. doi: 10.1016/j.chest.2021.03.003.
5
Letter to the Editor in response to the articles 'Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)' and 'Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.'.致编辑的信：回应文章《连花清瘟对新型冠状病毒（SARS-CoV-2）具有抗病毒和抗炎活性》及《六神胶囊通过抑制NF-κB信号通路显示出对新型冠状病毒SARS-CoV-2的抗病毒和抗炎能力》
Pharmacol Res. 2021 Jan;163:105289. doi: 10.1016/j.phrs.2020.105289. Epub 2020 Nov 13.
6
A five-day course of ivermectin may reduce the duration of COVID-19 illness.为期五天的伊维菌素疗程可能会缩短新冠病毒疾病的病程。
Int J Infect Dis. 2021 Sep;110:93-94. doi: 10.1016/j.ijid.2021.07.050. Epub 2021 Jul 26.
7
Ivermectin for COVID-19: Promising but not yet conclusive.用于治疗新冠肺炎的伊维菌素：有前景但尚无定论。
S Afr Med J. 2021 Jan 12;111(3):13187. doi: 10.7196/SAMJ.2021.v111i3.15522.
8
Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).关于伊维菌素对2019年冠状病毒病有效性的回顾性分析（ICON研究）的评论
Chest. 2021 May;159(5):2110-2111. doi: 10.1016/j.chest.2020.10.088.
9
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.阿齐霉素、利托那韦、洛匹那韦、奥司他韦、伊维菌素和肝素与 2019 年冠状病毒病和严重急性呼吸综合征冠状病毒-2 3C 样蛋白酶相互作用的分子对接。
J Nanosci Nanotechnol. 2021 Apr 1;21(4):2075-2089. doi: 10.1166/jnn.2021.19029.
10
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?秋水仙碱作为一种古老的抗炎药物，对新冠病毒肺炎是否有效？
J Clin Pharmacol. 2020 Jul;60(7):828-829. doi: 10.1002/jcph.1645. Epub 2020 May 23.
引用本文的文献
1
Pan-Cancer Analysis of the COVID-19 Causal Gene .新型冠状病毒肺炎致病基因的泛癌分析
ACS Omega. 2023 Mar 31;8(14):13153-13161. doi: 10.1021/acsomega.3c00407. eCollection 2023 Apr 11.
2
Combination of , and Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?在短期阿霉素介导的心脏毒性临床前模型中，[具体物质1]、[具体物质2]和[具体物质3]的联合使用改善心脏功能并降低促炎生物标志物：心脏肿瘤学的新前沿？ （注：原文中部分内容缺失，用[具体物质1]等表示）
J Cardiovasc Dev Dis. 2022 Nov 28;9(12):423. doi: 10.3390/jcdd9120423.
3
Potential therapeutic effects of Ivermectin in COVID-19.伊维菌素在 COVID-19 中的潜在治疗作用。
Exp Biol Med (Maywood). 2022 Aug;247(15):1388-1396. doi: 10.1177/15353702221099579. Epub 2022 Jun 10.
4
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis.伊维菌素用于预防和治疗新型冠状病毒肺炎：一项系统评价与Meta分析
Diagnostics (Basel). 2021 Sep 8;11(9):1645. doi: 10.3390/diagnostics11091645.
本文引用的文献
1
Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.炎症小体在 SARS-CoV-2 感染时被激活，并与 COVID-19 患者的严重程度相关。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20201707.
2
Can Glycine Mitigate COVID-19 Associated Tissue Damage and Cytokine Storm?甘氨酸能减轻与COVID-19相关的组织损伤和细胞因子风暴吗？
Radiat Res. 2020 Sep 16;194(3):199-201. doi: 10.1667/RADE-20-00146.1.
3
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
4
Serious Ivermectin Toxicity and Human Nonsense Mutations.严重的伊维菌素毒性与人类无义突变
N Engl J Med. 2020 Aug 20;383(8):787-789. doi: 10.1056/NEJMc1917344.
5
Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase.新型冠状病毒肺炎的血栓形成并发症可能反映出内皮组织因子表达上调，这取决于内体烟酰胺腺嘌呤二核苷酸磷酸氧化酶的激活。
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001337.
6
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.伊维菌素单独批准的剂量不是治疗 COVID-19 的理想剂量。
Clin Pharmacol Ther. 2020 Oct;108(4):762-765. doi: 10.1002/cpt.1889. Epub 2020 Jun 7.
7
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
8
Glycine Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Regulating NLRP3 Inflammasome and NRF2 Signaling.甘氨酸通过调节 NLRP3 炎性体和 NRF2 信号通路减轻脂多糖诱导的急性肺损伤。
Nutrients. 2020 Feb 26;12(3):611. doi: 10.3390/nu12030611.
9
Activated glycine receptors may decrease endosomal NADPH oxidase activity by opposing ClC-3-mediated efflux of chloride from endosomes.激活的甘氨酸受体可能通过拮抗 ClC-3 介导的内体氯离子外流来降低内体 NADPH 氧化酶的活性。
Med Hypotheses. 2019 Feb;123:125-129. doi: 10.1016/j.mehy.2019.01.012. Epub 2019 Jan 16.
10
Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris.疑似稳定型心绞痛患者血浆甘氨酸水平与急性心肌梗死风险
J Am Heart Assoc. 2015 Dec 31;5(1):e002621. doi: 10.1161/JAHA.115.002621.
Zotero 插件